septemb
novel
coronaviru
cov
call
middl
east
respiratori
syndrom
cov
merscov
isol
caus
agent
sever
pneumonia
sever
patient
middl
east
global
may
inform
total
laboratoryconfirm
case
infect
merscov
includ
death
primarili
middl
east
saudi
arabia
jordan
qatar
oman
kuwait
unit
arab
emir
also
europ
uk
franc
itali
germani
greec
north
africa
tunisia
egypt
asia
malaysia
unit
state
america
http
http
wwwcdcgovcoronavirusm
cov
close
relat
sever
acut
respiratori
syndrom
cov
sarscov
epidem
shortliv
alarm
result
approxim
case
death
sarscov
merscov
belong
famili
coronavirida
envelop
positivestrand
rna
virus
approxim
nucleotid
cov
repres
largest
rna
virus
wellcharacter
sarscov
two
overlap
open
read
frame
encompass
approxim
twothird
genom
translat
readthrough
ribosom
frameshift
mechan
allow
translat
overlap
read
frame
singl
polyprotein
wherea
translat
without
ribosom
frameshift
mechan
produc
polyprotein
later
cleav
two
viral
proteinas
proteas
papainlik
proteas
plp
yield
nonstructur
protein
essenti
viral
replic
remain
onethird
genom
encod
structur
protein
viru
includ
spike
envelop
e
membran
nucleocapsid
n
protein
basi
phylogen
analys
evolutionari
studi
shown
sarscov
origin
like
bat
report
transmit
human
aerosol
intermedi
host
like
palm
civet
infect
viru
therefor
zoonosi
cov
threat
due
abil
interspeci
transfer
human
popul
recapitul
novel
merscov
recent
studi
suggest
bat
dromedari
camel
serv
reservoir
viru
merscov
show
sarslik
symptom
follow
human
infect
includ
malais
rigor
fatigu
high
fever
indic
similar
influenza
later
progress
atyp
pneumonia
case
although
mani
antivir
agent
identifi
inhibit
sar
vitro
present
approv
antivir
agent
vaccin
avail
tackl
potenti
sar
sarslik
outbreak
mer
differ
part
viru
deem
viabl
target
includ
plp
rnadepend
rna
polymeras
rdrp
helicas
possibl
target
includ
e
protein
protein
n
protein
review
focus
publish
antivir
inhibitor
coronavirus
sarscov
consid
primari
viru
inhibitor
includ
replic
entri
inhibitor
develop
therapeut
purpos
sar
coronavirus
includ
novel
merscov
first
coronaviru
protein
studi
detail
includ
viral
proteinas
name
papainlik
proteas
plp
proteas
mpro
cleav
polyprotein
individu
polypeptid
requir
replic
transcript
follow
translat
messeng
rna
yield
polyprotein
first
autocleav
polyprotein
becom
matur
enzym
cleav
remain
downstream
nonstructur
protein
henc
essenti
viral
protein
viral
replic
cycl
result
becom
attract
target
antisar
drug
develop
inhibitor
among
first
sarscov
inhibitor
discov
screen
compound
librari
use
assay
util
fluorogen
peptid
substrat
structurebas
design
basi
crystal
structur
productbound
form
compound
identifi
includ
zinc
mercuri
conjug
diol
peptidomimet
bunsatur
ester
anilid
benzotriazol
acetamid
biphenyl
sulfon
glutam
acid
glutamin
peptid
possess
trifluoromethylketon
group
pyrimidinon
pyrazol
analog
also
inhibit
picornavirus
coxsackieviru
enteroviru
rhinoviru
coronaviru
picornaviru
dual
inhibitor
name
chemic
structur
publish
inhibitor
shown
figur
papain
like
proteas
plp
also
essenti
compon
sarscov
replic
machineri
plp
protein
part
synthes
polyprotein
replic
cleav
proteas
recognit
site
addit
proteas
activ
shown
deubiquitin
interferon
antagonist
activ
vitro
sinc
homologu
found
coronavirus
also
propos
good
target
drug
discoveri
sarscov
human
coronavirus
recent
frieman
et
al
develop
yeastbas
assay
screen
small
molecul
block
sarscov
replic
basi
inhibit
plp
basi
screen
stimul
express
saccharomyc
cerevisia
caus
pronounc
slow
growth
phenotyp
use
principl
screen
small
molecul
librari
compound
specif
prevent
slow
growth
phenotyp
compound
valid
cell
cultur
model
efficaci
sarscov
replic
well
known
enzymat
function
author
found
five
compound
revers
slow
growth
phenotyp
yeast
one
compound
figur
consider
block
sarscov
replic
vitro
ec
mm
effect
specif
sarscov
replic
effect
influenza
viru
replic
observ
mm
inhibitori
compound
anoth
compound
shown
inhibit
proteas
activ
cell
cultur
assay
could
prevent
viru
replic
could
inhibit
proteas
deubiquitinas
antiifn
activ
therefor
suggest
compound
may
inhibit
yet
unknown
novel
activ
requir
viral
replic
may
inhibit
cellular
factor
regul
function
infect
cell
helicas
protein
catalyz
separ
duplex
oligonucleotid
singl
strand
atpdepend
reaction
basi
activ
helicas
divid
two
type
unwind
duplex
direct
unwind
direct
helicas
requir
molecular
mechan
transduc
chemic
energi
gener
atpas
activ
oligonucleotid
strand
separ
displac
activ
function
helicas
positivesens
rna
virus
includ
nucleic
acid
separ
melt
highli
stabl
secondari
structur
within
genom
rna
order
increas
translat
effici
polyprotein
consid
helicas
function
viral
helicas
stand
strong
antivir
target
helicas
sarscov
call
potenti
inhibitor
identifi
inhibitor
inhibit
interf
unwind
atpas
activ
includ
bananin
deriv
bananin
class
antivir
compound
exclus
structur
signatur
incorpor
trioxaadamantan
moieti
coval
bound
pyridox
deriv
six
member
class
compound
synthes
tanner
et
al
compound
bananin
iodobananin
vanillinbananin
ansabananin
eubananin
adeninobananin
six
compound
bananin
iodobananin
vanillinbananin
eubananin
effect
inhibit
helicas
activ
inhibit
atpas
activ
helicas
ic
valu
rang
mm
bananin
also
antivir
specif
coronavirus
adedeji
sarafiano
shown
exhibit
antivir
activ
sarscov
cell
cultur
assay
less
mm
structur
vanillinbananin
shown
figur
deriv
use
scaffold
two
arylmethyloxi
substitu
instal
result
deriv
includ
chromon
chlorobenzyloxi
iodobenzyloxi
substitu
figur
compound
similar
bananin
also
inhibit
unwind
activ
sarscov
inhibit
atpas
activ
helicas
compar
ec
mm
although
compound
portend
promis
therapi
potenti
abil
compound
inhibit
atpas
activ
cellular
atpas
kinas
may
affect
cellular
activ
therebi
creat
risk
cytotox
studi
report
aryl
diketoacid
compound
figur
select
inhibit
duplex
dna
unwind
activ
sarscov
without
significantli
inhibit
atpas
activ
howev
effect
compound
unwind
activ
doublestrand
rna
dsrna
replic
sarscov
determin
recent
report
reveal
inhibitor
inhibit
unwind
atpas
enzymat
nucleic
acid
bind
activ
use
biochem
analys
author
demonstr
compound
figur
noncompetit
inhibitor
respect
major
substrat
name
nucleic
acid
atp
sinc
compound
inhibit
bind
hydrolysi
nucleic
acid
atp
coupl
fact
bind
nucleic
acid
substrat
author
suggest
may
inhibit
unwind
activ
interf
conform
chang
cours
reaction
transloc
nucleic
acid
moreov
also
shown
antivir
resist
effici
inhibitor
viral
replic
sarscov
replicon
live
viral
assay
recent
shown
exhibit
broadspectrum
activ
coronavirus
includ
merscov
mous
hepat
viru
mhv
viral
entri
essenti
step
viru
replic
cycl
target
therapi
entri
inhibitor
sever
virus
identifi
exampl
includ
rfi
small
molecul
inhibit
entri
respiratori
syncyti
viru
bind
hydrophob
pocket
fusion
f
glycoprotein
inhibitor
report
block
hiv
entri
use
differ
strategi
maraviroc
entri
inhibitor
hiv
target
host
protein
use
coreceptor
hiv
entri
enfuvirtid
peptid
also
block
viral
entri
bind
viral
transmembran
protein
block
final
stage
fusion
target
cell
monoclon
antibodi
current
clinic
trial
includ
prevent
hiv
entri
bind
either
viral
surfac
glycoprotein
coreceptor
surfac
glycoprotein
sarscov
sarss
two
constitu
compris
receptor
bind
domain
rbd
compris
fusion
peptid
sarscov
gain
entri
permiss
cell
interact
sarss
rbd
cell
surfac
receptor
angiotensin
convert
enzym
figur
follow
interact
endocytosi
occur
endosom
within
region
low
ph
cell
sarss
cleav
cellular
proteas
call
cathepsin
l
figur
lead
exposur
domain
spike
protein
membran
fusion
report
also
suggest
possibl
fusion
sarssexpress
cell
receptorexpress
cell
phindepend
environ
cell
surfac
possibl
target
sar
viral
entri
thu
includ
cathepsin
l
interact
membran
fusion
figur
number
studi
identifi
inhibitor
interfer
target
dipeptid
epoxyketon
calpain
inhibitor
iii
oxocarbaz
cathepsin
l
inhibitor
figur
although
first
four
compound
peptidomimet
natur
figur
c
figur
small
molecul
cathepsin
l
inhibitor
like
improv
bioavail
other
compound
shown
inhibit
sar
viral
entri
hinder
abil
cathepsin
l
cleav
therebi
prevent
fusion
viral
envelop
host
cell
membran
follow
endocytosi
sar
viral
entri
inhibitor
includ
figur
figur
naae
n
laziridineethanamin
small
molecul
compound
prevent
fusion
viral
membran
host
cellular
membran
fig
naae
act
block
earli
interact
sarss
receptor
sarscov
angiotensin
convert
enzym
figur
naae
uniqu
small
molecul
entri
inhibitor
inhibit
catalyt
activ
sproteininduc
cellcel
fusion
although
dual
inhibitori
antivir
specif
coronavirus
adedeji
sarafiano
effect
catalyt
activ
sarscov
bind
expect
catalyt
site
distinct
sproteinbind
domain
naae
show
antivir
activ
overexpress
ace
shown
caus
hypertens
counterbalanc
vasodil
henc
inhibit
naae
stand
potenti
risk
hypertens
current
approv
drug
treatment
sarscov
infect
initi
outbreak
sar
number
medic
includ
ribavirin
without
corticosteroid
interferon
corticosteroid
ribavirin
proteas
inhibitor
encourag
outcom
definit
treatment
regimen
clearli
establish
recent
combin
ribavirin
shown
vitro
synergist
activ
merscov
albeit
higher
concentr
drug
known
pharmacolog
properti
therefor
wide
avail
use
treatment
viral
infect
hepat
c
viru
albeit
advers
side
effect
includ
hemolyt
anemia
elev
transaminas
level
bradycardia
depress
suicid
relaps
drug
abuseoverdos
bacteri
infect
mani
other
interferon
ribavirin
treatment
side
effect
http
wwwhepatitisvagovproviderreview
treatmentsideeffectsasp
henc
new
outbreak
merscov
infect
optim
develop
aforement
lead
compound
inhibitor
known
new
mechan
action
becom
import
therapeut
purpos
report
compound
clinic
trial
first
report
crystal
structur
sever
acut
respiratori
syndrom
viru
main
proteas
differ
ph
complex
specif
inhibitor
